RNAM
Avidity Biosciences Inc
Price Chart
No historical data available
Latest Quote
$72.82
Current Price| Day High | $73.04 |
| Day Low | $72.75 |
Stock Information
| Shares Outstanding | 154.48M |
| Total Debt | $49.25M |
| Cash Equivalents | $1.70B |
| Revenue | $18.75M |
| Net Income | $-684.63M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $11.25B |
| EPS (TTM) | $-4.19 |
| Exchange | NGM |
Recent Price History
No history data available. Data will be fetched automatically.
About Avidity Biosciences Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in clinical development, such as Delpacibart zotadirsen which is in Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy; Delpacibart etedesiran which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; and Delpacibart braxlosiran that is in Phase 1/2 development stage for the treatment of facioscapulohumeral muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. As of February 27, 2026, Avidity Biosciences, Inc. operates as a subsidiary of Novartis AG.
đ° Latest News
Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger
Insider Monkey âĸ 2026-02-27T21:05:40Z
European Stocks Mostly Higher in Friday Trading; French GDP Growth Slows, Inflation Rises
MT Newswires âĸ 2026-02-27T16:51:17ZAtrium spins out of Avidity, aiming to target rare heart diseases with RNA
BioPharma Dive âĸ 2026-02-27T12:58:42Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $10,897,000 | $9,560,000 | $9,224,000 | $9,326,000 |
| Operating Revenue | $10,897,000 | $9,560,000 | $9,224,000 | $9,326,000 |
| Expenses | ||||
| Total Expenses | $389,833,000 | $245,158,000 | $188,137,000 | $127,377,000 |
| Other Income Expense | $-248,000 | $-594,000 | $-57,000 | $-62,000 |
| Other Non Operating Income Expenses | $-248,000 | $-594,000 | $-57,000 | $-62,000 |
| Net Non Operating Interest Income Expense | $56,882,000 | $23,972,000 | $4,975,000 | $104,000 |
| Operating Expense | $389,833,000 | $245,158,000 | $188,137,000 | $127,377,000 |
| General And Administrative Expense | $86,240,000 | $54,190,000 | $37,733,000 | $26,195,000 |
| Interest Expense | - | - | $0 | $0 |
| Interest Expense Non Operating | - | - | $0 | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-322,302,000 | $-212,220,000 | $-173,995,000 | $-118,009,000 |
| Net Interest Income | $56,882,000 | $23,972,000 | $4,975,000 | $104,000 |
| Interest Income | $56,882,000 | $23,972,000 | $4,975,000 | $104,000 |
| Normalized Income | $-322,302,000 | $-212,220,000 | $-173,995,000 | $-118,009,000 |
| Net Income From Continuing And Discontinued Operation | $-322,302,000 | $-212,220,000 | $-173,995,000 | $-118,009,000 |
| Total Operating Income As Reported | $-378,936,000 | $-235,598,000 | $-178,913,000 | $-118,051,000 |
| Net Income Common Stockholders | $-322,302,000 | $-212,220,000 | $-173,995,000 | $-118,009,000 |
| Net Income | $-322,302,000 | $-212,220,000 | $-173,995,000 | $-118,009,000 |
| Net Income Including Noncontrolling Interests | $-322,302,000 | $-212,220,000 | $-173,995,000 | $-118,009,000 |
| Net Income Continuous Operations | $-322,302,000 | $-212,220,000 | $-173,995,000 | $-118,009,000 |
| Pretax Income | $-322,302,000 | $-212,220,000 | $-173,995,000 | $-118,009,000 |
| Interest Income Non Operating | $56,882,000 | $23,972,000 | $4,975,000 | $104,000 |
| Operating Income | $-378,936,000 | $-235,598,000 | $-178,913,000 | $-118,051,000 |
| Per Share | ||||
| Diluted EPS | $-2.89 | $-2.91 | $-3.34 | $-5.70 |
| Basic EPS | $-2.89 | $-2.91 | $-3.34 | $-5.70 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-376,160,000 | $-233,497,000 | $-177,526,000 | $-117,412,000 |
| Reconciled Depreciation | $2,776,000 | $2,101,000 | $1,387,000 | $639,000 |
| EBITDA (Bullshit earnings) | $-376,160,000 | $-233,497,000 | $-177,526,000 | $-117,412,000 |
| EBIT | $-378,936,000 | $-235,598,000 | $-178,913,000 | $-118,051,000 |
| Diluted Average Shares | $111,582,000 | $73,012,000 | $52,162,000 | $20,714,000 |
| Basic Average Shares | $111,582,000 | $73,012,000 | $52,162,000 | $20,714,000 |
| Diluted NI Availto Com Stockholders | $-322,302,000 | $-212,220,000 | $-173,995,000 | $-118,009,000 |
| Research And Development | $303,593,000 | $190,968,000 | $150,404,000 | $101,182,000 |
| Selling General And Administration | $86,240,000 | $54,190,000 | $37,733,000 | $26,195,000 |
| Other Gand A | $86,240,000 | $54,190,000 | $37,733,000 | $26,195,000 |
Fetched: 2026-03-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,424,959,000 | $500,764,000 | $578,075,000 | $381,430,000 |
| Total Assets | $1,563,895,000 | $628,555,000 | $638,800,000 | $427,580,000 |
| Total Non Current Assets | $21,605,000 | $17,248,000 | $15,858,000 | $16,439,000 |
| Other Non Current Assets | $3,316,000 | $596,000 | $849,000 | $850,000 |
| Current Assets | $1,542,290,000 | $611,307,000 | $622,942,000 | $411,141,000 |
| Prepaid Assets | $12,571,000 | $7,333,000 | $8,340,000 | $5,598,000 |
| Receivables | $28,222,000 | $8,623,000 | $3,875,000 | - |
| Accrued Interest Receivable | $28,222,000 | $7,518,000 | $1,511,000 | - |
| Accounts Receivable | $0 | $1,105,000 | $2,364,000 | - |
| Cash Cash Equivalents And Short Term Investments | $1,501,497,000 | $595,351,000 | $610,727,000 | $405,543,000 |
| Cash And Cash Equivalents | $219,868,000 | $185,082,000 | $340,396,000 | $320,448,000 |
| Other Current Assets | - | - | $12,215,000 | $5,598,000 |
| Debt | ||||
| Total Debt | $6,801,000 | $9,852,000 | $10,687,000 | $11,729,000 |
| Long Term Debt And Capital Lease Obligation | $2,957,000 | $6,213,000 | $7,582,000 | $9,960,000 |
| Current Debt And Capital Lease Obligation | $3,844,000 | $3,639,000 | $3,105,000 | $1,769,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $138,936,000 | $127,791,000 | $60,725,000 | $46,150,000 |
| Total Non Current Liabilities Net Minority Interest | $40,918,000 | $47,111,000 | $8,817,000 | $16,492,000 |
| Non Current Deferred Liabilities | $37,961,000 | $40,898,000 | $1,235,000 | $6,532,000 |
| Current Liabilities | $98,018,000 | $80,680,000 | $51,908,000 | $29,658,000 |
| Current Deferred Liabilities | $20,987,000 | $28,365,000 | $5,041,000 | $4,864,000 |
| Payables And Accrued Expenses | $69,524,000 | $34,341,000 | $32,572,000 | $14,085,000 |
| Payables | $8,461,000 | $8,809,000 | $4,637,000 | $2,806,000 |
| Accounts Payable | $8,461,000 | $8,809,000 | $4,637,000 | $2,806,000 |
| Equity | ||||
| Common Stock Equity | $1,424,959,000 | $500,764,000 | $578,075,000 | $381,430,000 |
| Total Equity Gross Minority Interest | $1,424,959,000 | $500,764,000 | $578,075,000 | $381,430,000 |
| Stockholders Equity | $1,424,959,000 | $500,764,000 | $578,075,000 | $381,430,000 |
| Gains Losses Not Affecting Retained Earnings | $2,902,000 | $125,000 | $-2,698,000 | $-187,000 |
| Other Equity Adjustments | $2,902,000 | $125,000 | $-2,698,000 | $-187,000 |
| Retained Earnings | $-893,066,000 | $-570,764,000 | $-358,544,000 | $-184,549,000 |
| Other | ||||
| Ordinary Shares Number | $119,893,000 | $79,275,000 | $69,768,000 | $47,754,000 |
| Share Issued | $119,893,000 | $79,275,000 | $69,768,000 | $47,754,000 |
| Tangible Book Value | $1,424,959,000 | $500,764,000 | $578,075,000 | $381,430,000 |
| Invested Capital | $1,424,959,000 | $500,764,000 | $578,075,000 | $381,430,000 |
| Working Capital | $1,444,272,000 | $530,627,000 | $571,034,000 | $381,483,000 |
| Capital Lease Obligations | $6,801,000 | $9,852,000 | $10,687,000 | $11,729,000 |
| Total Capitalization | $1,424,959,000 | $500,764,000 | $578,075,000 | $381,430,000 |
| Additional Paid In Capital | $2,315,111,000 | $1,071,395,000 | $939,310,000 | $566,161,000 |
| Capital Stock | $12,000 | $8,000 | $7,000 | $5,000 |
| Common Stock | $12,000 | $8,000 | $7,000 | $5,000 |
| Non Current Deferred Revenue | $37,961,000 | $40,898,000 | $1,235,000 | $6,532,000 |
| Long Term Capital Lease Obligation | $2,957,000 | $6,213,000 | $7,582,000 | $9,960,000 |
| Current Deferred Revenue | $20,987,000 | $28,365,000 | $5,041,000 | $4,864,000 |
| Current Capital Lease Obligation | $3,844,000 | $3,639,000 | $3,105,000 | $1,769,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,663,000 | $14,335,000 | $11,190,000 | $8,940,000 |
| Current Accrued Expenses | $61,063,000 | $25,532,000 | $27,935,000 | $11,279,000 |
| Net PPE | $18,289,000 | $16,652,000 | $15,009,000 | $15,589,000 |
| Accumulated Depreciation | $-7,997,000 | $-5,221,000 | $-3,120,000 | $-1,733,000 |
| Gross PPE | $26,286,000 | $21,873,000 | $18,129,000 | $17,322,000 |
| Leases | $288,000 | $288,000 | $249,000 | $249,000 |
| Construction In Progress | $3,959,000 | $0 | - | - |
| Other Properties | $14,180,000 | $19,479,000 | $15,972,000 | $15,559,000 |
| Machinery Furniture Equipment | $2,240,000 | $2,106,000 | $1,908,000 | $1,514,000 |
| Buildings And Improvements | $5,619,000 | - | - | - |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $1,281,629,000 | $410,269,000 | $270,331,000 | $85,095,000 |
| Preferred Stock | - | - | - | $0 |
Fetched: 2026-03-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-307,936,000 | $-123,292,000 | $-139,091,000 | $-98,553,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-300,870,000 | $-119,064,000 | $-136,268,000 | $-94,813,000 |
| Cash Flow From Continuing Operating Activities | $-300,870,000 | $-119,064,000 | $-136,268,000 | $-94,813,000 |
| Operating Gains Losses | - | - | - | $-16,000 |
| Investing Activities | ||||
| Capital Expenditure | $-7,066,000 | $-4,228,000 | $-2,823,000 | $-3,740,000 |
| Investing Cash Flow | $-854,201,000 | $-130,070,000 | $-189,955,000 | $-82,517,000 |
| Cash Flow From Continuing Investing Activities | $-854,201,000 | $-130,070,000 | $-189,955,000 | $-82,517,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $1,000,549,000 | $91,737,000 | $344,779,000 | $174,677,000 |
| Financing Cash Flow | $1,192,357,000 | $93,864,000 | $346,171,000 | $176,316,000 |
| Cash Flow From Continuing Financing Activities | $1,192,357,000 | $93,864,000 | $346,171,000 | $176,316,000 |
| Net Common Stock Issuance | $1,000,549,000 | $91,737,000 | $344,779,000 | $174,677,000 |
| Common Stock Issuance | $1,000,549,000 | $91,737,000 | $344,779,000 | $174,677,000 |
| Net Preferred Stock Issuance | - | $31,190,000 | $0 | $0 |
| Preferred Stock Issuance | - | $31,190,000 | $0 | $0 |
| Net Other Financing Charges | - | - | - | $-11,262,000 |
| Cash Dividends Paid | - | - | - | $0 |
| Other | ||||
| End Cash Position | $222,663,000 | $185,377,000 | $340,647,000 | $320,699,000 |
| Beginning Cash Position | $185,377,000 | $340,647,000 | $320,699,000 | $321,713,000 |
| Changes In Cash | $37,286,000 | $-155,270,000 | $19,948,000 | $-1,014,000 |
| Proceeds From Stock Option Exercised | $191,808,000 | $2,127,000 | $1,392,000 | $1,639,000 |
| Net Investment Purchase And Sale | $-847,135,000 | $-125,842,000 | $-187,132,000 | $-78,777,000 |
| Sale Of Investment | $586,400,000 | $335,160,000 | $168,705,000 | $6,580,000 |
| Purchase Of Investment | $-1,433,535,000 | $-461,002,000 | $-355,837,000 | $-85,357,000 |
| Net PPE Purchase And Sale | $-7,066,000 | $-4,228,000 | $-2,823,000 | $-3,740,000 |
| Purchase Of PPE | $-7,066,000 | $-4,228,000 | $-2,823,000 | $-3,740,000 |
| Change In Working Capital | $-14,557,000 | $61,129,000 | $7,067,000 | $4,643,000 |
| Change In Other Working Capital | $-10,315,000 | $62,987,000 | $-5,120,000 | $-4,444,000 |
| Change In Other Current Liabilities | $-3,696,000 | $-3,328,000 | $-1,762,000 | $-234,000 |
| Change In Payables And Accrued Expense | $24,511,000 | $4,914,000 | $20,565,000 | $11,831,000 |
| Change In Accrued Expense | $-10,672,000 | $3,145,000 | $2,250,000 | $5,788,000 |
| Change In Payable | $35,183,000 | $1,769,000 | $18,315,000 | $6,043,000 |
| Change In Account Payable | $35,183,000 | $1,769,000 | $18,315,000 | $6,043,000 |
| Change In Prepaid Assets | $-25,057,000 | $-3,444,000 | $-6,616,000 | $-2,510,000 |
| Other Non Cash Items | $3,297,000 | $2,978,000 | $2,749,000 | $679,000 |
| Stock Based Compensation | $51,363,000 | $38,222,000 | $27,139,000 | $17,056,000 |
| Amortization Of Securities | $-21,447,000 | $-11,274,000 | $-615,000 | $179,000 |
| Depreciation Amortization Depletion | $2,776,000 | $2,101,000 | $1,387,000 | $639,000 |
| Depreciation And Amortization | $2,776,000 | $2,101,000 | $1,387,000 | $639,000 |
| Depreciation | $2,776,000 | $2,101,000 | $1,387,000 | $639,000 |
| Net Income From Continuing Operations | $-322,302,000 | $-212,220,000 | $-173,995,000 | $-118,009,000 |
| Repayment Of Debt | - | - | $0 | $0 |
| Interest Paid Supplemental Data | - | - | $0 | $0 |
| Net Issuance Payments Of Debt | - | - | $0 | $0 |
| Net Long Term Debt Issuance | - | - | $0 | $0 |
| Long Term Debt Payments | - | - | $0 | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | $-16,000 |
Fetched: 2026-03-02